Retraction

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis

Paper Information

Record ID:
44538
Author(s):
Amir Abbas Momtazi-Borojeni
Mahmoud Reza Jaafari
Ali Badiee
Maciej Banach
Amirhossein Sahebkar
Journal:
BMC Medicine ( Springer - Biomed Central (BMC) )
Publication Date:
December 10, 2019
Retraction Date:
May 04, 2023 (2.6 years years ago)
Subjects:
Broad Categories:
Biology Toxicology
Institutions:
Countries:
🇮🇷 Iran 🇵🇱 Poland
Article Type:
Research Article
Publisher:
Springer - Biomed Central (BMC)
Open Access:
Yes
DOI:
10.1186/s12916-019-1457-8
PubMed ID:
31818299
Retraction PubMed ID:
37143044

Retraction Details

Retraction Reasons:
Nature of Retraction:

Retraction

Retraction Notice:
10.1186/s12916-023-02884-w

Citations (64)

64
Total Citations
11
Post-Retraction
(17.2%)
53
Pre-Retraction
0
Same Day
Post-Retraction Citation Analysis
2 Within 30 days
8 Within 1 year
0 After 2+ years
595 Days since retraction (latest)
A Study of Retractions in Pharmacy and Pharmaceutical Research in the PMC Database
Unknown Authors
Advances in medical education, research, and ethics (AMERE) book series
Published: Dec 2024
595 days after retraction
PCSK9 in metabolism and diseases
Amir Ajoolabady, Domenico Praticò, Mohsen Mazidi et al. (9 authors)
Metabolism
Published: Nov 2024
11 citations
560 days after retraction
PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model
Yang Yang, Yeying Wang, Yuwen Wang et al. (5 authors)
PeerJ Open Access
Published: Aug 2024
1 citation
468 days after retraction
New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
Stephen J. Nicholls, Adam J. Nelson
Expert Opinion on Therapeutic Targets
Published: May 2024
3 citations
365 days after retraction
Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
Khursheed Muzammil, Mohammad Hosseini Hooshiar, Shirin Varmazyar et al. (8 authors)
Microbial Cell Factories Open Access
Published: Mar 2024
17 citations
326 days after retraction
Stromal cell-derived factor-1 alpha improves cardiac function in a novel diet-induced coronary atherosclerosis model, the SR-B1ΔCT/LDLR KO mouse
Danielle M. Mullis, Amanda Padilla-Lopez, Hui Wang et al. (10 authors)
Atherosclerosis Open Access
Published: Mar 2024
3 citations
323 days after retraction
Dyslipidemia: A Narrative Review on Pharmacotherapy
Lucas Dorneles de Oliveira, Arthur Cicupira Rodrigues de Assis, Viviane Z. Rocha et al. (5 authors)
Pharmaceuticals Open Access
Published: Feb 2024
11 citations
295 days after retraction
A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates
Alexandra Fowler, Koen K. A. Van Rompay, Maureen Sampson et al. (11 authors)
npj Vaccines Open Access
Published: Sep 2023
23 citations
147 days after retraction
Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations
Zhicheng Xiao, Yi Li, Liyan Xiong et al. (12 authors)
Advanced Science Open Access
Published: Sep 2023
15 citations
131 days after retraction
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Reindert F. Oostveen, Amit V. Khera, Sekar Kathiresan et al. (8 authors)
Arteriosclerosis Thrombosis and Vascular Biology
Published: Jun 2023
19 citations
28 days after retraction
A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates
Alexandra Fowler, Koen K. A. Van Rompay, Maureen Sampson et al. (11 authors)
bioRxiv (Cold Spring Harbor Laboratory) Open Access
Published: May 2023
4 citations
11 days after retraction
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Julia Brandts, Kausik K. Ray
Nature Reviews Cardiology
Published: Apr 2023
67 citations
21 days before retraction
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Andrew S. Bell, Josephin Wagner, Daniel B. Rosoff et al. (4 authors)
Neuroscience & Biobehavioral Reviews
Published: Apr 2023
20 citations
31 days before retraction
Two decades of vaccine development against atherosclerosis
Miguel A. Moreno‐Gonzalez, Oscar A. Ortega‐Rivera, Nicole F. Steinmetz
Nano Today Open Access
Published: Mar 2023
14 citations
34 days before retraction
Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes
Victoria Serhiyenko, A.A. Serhiyenko
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) Open Access
Published: Mar 2023
45 days before retraction
Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review
Abdulmajeed Abdulghani A. Sindi
Journal of Lipids Open Access
Published: Mar 2023
7 citations
57 days before retraction
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Stephen J. Nicholls
Kardiologia Polska Open Access
Published: Feb 2023
21 citations
65 days before retraction
Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
Yanan Wang, Dan Fang, Qinzhi Yang et al. (8 authors)
Frontiers in Immunology Open Access
Published: Feb 2023
16 citations
71 days before retraction
Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
Anastasia V. Poznyak, Vasily N. Sukhorukov, Ilya I. Eremin et al. (6 authors)
Biomedicines Open Access
Published: Feb 2023
5 citations
84 days before retraction
Nanoliposomes as safe and efficient drug delivery nanovesicles
Zaynab Fatfat, Mia Karam, Batoul Maatouk et al. (5 authors)
Elsevier eBooks
Published: Jan 2023
24 citations
123 days before retraction
PCSK9 Inhibitors and Coronary Atherosclerosis: Insights From Recent Intravascular Imaging Clinical Trials
Masashi Fujino, Stephen J. Nicholls
CardioMetabolic Syndrome Journal
Published: Jan 2023
123 days before retraction
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Alex Bobik, Neale Cohen, Alicia J. Jenkins et al. (8 authors)
Contemporary diabetes Open Access
Published: Jan 2023
123 days before retraction
Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice
Amir Abbas Momtazi‐Borojeni, Maciej Banach, Sayed Abbas Tabatabaei et al. (4 authors)
Biomedicine & Pharmacotherapy Open Access
Published: Dec 2022
7 citations
125 days before retraction
A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
Louise Goksøyr, Magdalena Skrzypczak, Maureen Sampson et al. (9 authors)
Vaccines Open Access
Published: Dec 2022
13 citations
135 days before retraction
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
Malak Alannan, Nabil G. Seidah, Aksam Merched
Cells Open Access
Published: Dec 2022
8 citations
136 days before retraction
The Potential of Nanoliposome-Encapsulated PCSK9 Vaccine for Active Immunization Against Atherosclerosis: A Review
Anindya Amanda Damayanti, Riana Rahmawati, Amany Taqiyyah Wardhani et al. (5 authors)
Unknown Journal Open Access
Published: Dec 2022
137 days before retraction
New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
S. К. Zyryanov, О. И. Бутранова
Russian Journal of Cardiology Open Access
Published: Dec 2022
7 citations
148 days before retraction
Current progress in the development of prophylactic and therapeutic vaccines
Tingting Li, Ciying Qian, Ying Gu et al. (6 authors)
Science China Life Sciences Open Access
Published: Dec 2022
37 citations
153 days before retraction
Advances in imaging and treatment of atherosclerosis based on organic nanoparticles
Shuangshuang Tu, Wenming He, Jinru Han et al. (5 authors)
APL Bioengineering Open Access
Published: Dec 2022
12 citations
154 days before retraction
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Amir Abbas Momtazi‐Borojeni, Maciej Banach, Massimiliano Ruscica et al. (4 authors)
Expert Review of Clinical Pharmacology
Published: Oct 2022
19 citations
213 days before retraction
The Immunogenic Potential of PCSK9 Peptide Vaccine in Mice
Sarina Ataei, Amir Abbas Momtazi‐Borojeni, Shiva Ganjali et al. (5 authors)
Current Medicinal Chemistry
Published: Sep 2022
9 citations
216 days before retraction
PCSK9 Inhibition: From Current Advances to Evolving Future
Chunping Liu, Jing Chen, Huiqi Chen et al. (15 authors)
Cells Open Access
Published: Sep 2022
67 citations
223 days before retraction
Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling
Zhengyao Qian, Jianping Zhao
Journal of Microbiology and Biotechnology Open Access
Published: Sep 2022
4 citations
223 days before retraction
The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.
Sarina Ataei, Shiva Ganjali, Maciej Banach et al. (5 authors)
Archives of Medical Science Open Access
Published: Jul 2022
9 citations
299 days before retraction
Targeted Strategy in Lipid-Lowering Therapy
Ezgi Dayar, Oľga Pecháňová
Biomedicines Open Access
Published: May 2022
40 citations
361 days before retraction
Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism
Xuan Xiao, Yonghong Luo, Daoquan Peng
Frontiers in Cardiovascular Medicine Open Access
Published: Apr 2022
22 citations
370 days before retraction
Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease
Zhan Zhang, Rinkoo Dalan, Zhenyu Hu et al. (11 authors)
Advanced Materials Open Access
Published: Apr 2022
119 citations
373 days before retraction
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Peng Kong, Ziyang Cui, Xiao-Fu Huang et al. (6 authors)
Signal Transduction and Targeted Therapy Open Access
Published: Apr 2022
662 citations
377 days before retraction
Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition
Maciej Banach, Peter E. Penson
European Journal of Preventive Cardiology Open Access
Published: Feb 2022
5 citations
450 days before retraction
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Bushra Hassan Marouf, Zohaib Iqbal, Jamal Basheer Mohamad et al. (9 authors)
Clinical Therapeutics
Published: Feb 2022
9 citations
457 days before retraction
Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review
Stefano Bellosta, Clara Rossi, А. С. Алиева et al. (6 authors)
Cardiovascular Drugs and Therapy
Published: Jan 2022
8 citations
476 days before retraction
A Comprehensive Review of PCSK9 Inhibitors
Caroline Coppinger, Mohammad Reza Movahed, Veronica Azemawah et al. (6 authors)
Journal of Cardiovascular Pharmacology and Therapeutics Open Access
Published: Jan 2022
66 citations
488 days before retraction
Cytokines associated with immune response in atherosclerosis.
Jiqing Ma, Jianhua Luo, Yudong Sun et al. (4 authors)
PubMed
Published: Jan 2022
18 citations
488 days before retraction
Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies
Li Li, Sainan Liu, Jianying Tan et al. (8 authors)
Journal of Tissue Engineering Open Access
Published: Jan 2022
22 citations
488 days before retraction
CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities
Harry E. Walker, Manfredi Rizzo, Zlatko Fras et al. (6 authors)
Metabolites Open Access
Published: Dec 2021
19 citations
511 days before retraction
Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
Patrice Marqués, Elena Domingo, Arantxa Rubio et al. (8 authors)
Biomedicine & Pharmacotherapy Open Access
Published: Dec 2021
27 citations
518 days before retraction
PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
Amir Abbas Momtazi‐Borojeni, Matteo Pirro, Suowen Xu et al. (4 authors)
Current Medicinal Chemistry
Published: Oct 2021
11 citations
552 days before retraction
Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats
Amir Abbas Momtazi‐Borojeni, Mahmoud Reza Jaafari, Elham Abdollahi et al. (5 authors)
Journal of Diabetes Research Open Access
Published: Aug 2021
10 citations
611 days before retraction
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sai Sahana Sundararaman, Yvonne Döring, Emiel P. C. van der Vorst
Biomedicines Open Access
Published: Jul 2021
50 citations
665 days before retraction
Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
Amir Abbas Momtazi‐Borojeni, Mahmoud Reza Jaafari, Maciej Banach et al. (6 authors)
Vaccines Open Access
Published: Jul 2021
34 citations
667 days before retraction
Quick Stats
Total Citations: 64
Years Since Retraction: 2.6 years
Open Access: Yes
Last Checked: Jul 24, 2025
Related Papers
Infliximab Substantially Re-Silenced Wnt/Β-Catenin Signalin…
Journal of Biochemical and Molecular Toxicology • 10 citations
Amelioration of thioacetamide-induced hepatic encephalopath…
Environmental Science and Pollution Research • 22 citations
DNA barcoding detects contamination and substitution in Nor…
BMC Medicine • 486 citations
The assessment of the protective impact of spidroin extract…
Environmental Science and Pollution Research • 19 citations
3,4-Methylenedioxymethamphetamine causes retinal damage in …
Human and Experimental Toxicology • 4 citations
Actions
More from this journal Similar subjects View Original Paper View Retraction Notice